- $605.38m
- $422.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.53 | ||
| Price to Tang. Book | 2.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.94% | ||
| Return on Equity | -27.1% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 0.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.
Directors
- Andrew Levin NEC (44)
- Robert Azelby CEO (53)
- Erin Lavelle CFO (43)
- Valerie Morisset EVP (51)
- James Bucher EVP (54)
- Amy Chappell EXO
- Judith Dunn IND (59)
- Leone Patterson IND (58)
- Liam Ratcliffe IND (58)
- Adam Rosenberg IND (51)
- Simon Tate IND (55)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 18th, 2018
- Public Since
- August 10th, 2021
- No. of Shareholders
- 13
- No. of Employees
- 28
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 57,436,255
- Address
- 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS, 02481
- Web
- https://climbbio.com/
- Phone
- +1 3026365400
- Contact
- Carlo Tanzi
- Auditors
- PricewaterhouseCoopers LLP
Latest News for CLYM
Upcoming Events for CLYM
Similar to CLYM
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
As of Today at 02:01 UTC, shares in Climb Bio are trading at $10.54. This share price information is delayed by 15 minutes.
Shares in Climb Bio last closed at $10.54 and the price had moved by +411.65% over the past 365 days. In terms of relative price strength the Climb Bio share price has outperformed the S&P500 Index by +349.89% over the past year.
The overall consensus recommendation for Climb Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreClimb Bio does not currently pay a dividend.
Climb Bio does not currently pay a dividend.
Climb Bio does not currently pay a dividend.
To buy shares in Climb Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $10.54, shares in Climb Bio had a market capitalisation of $605.38m.
Here are the trading details for Climb Bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CLYM
Based on an overall assessment of its quality, value and momentum Climb Bio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Climb Bio is $27.87. That is 164.42% above the last closing price of $10.54.
Analysts covering Climb Bio currently have a consensus Earnings Per Share (EPS) forecast of -$0.80 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Climb Bio. Over the past six months, its share price has outperformed the S&P500 Index by +7.95%.
As of the last closing price of $10.54, shares in Climb Bio were trading +3.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Climb Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Climb Bio's management team is headed by:
- Andrew Levin - NEC
- Robert Azelby - CEO
- Erin Lavelle - CFO
- Valerie Morisset - EVP
- James Bucher - EVP
- Amy Chappell - EXO
- Judith Dunn - IND
- Leone Patterson - IND
- Liam Ratcliffe - IND
- Adam Rosenberg - IND
- Simon Tate - IND